Scinai Immunotherapeutics Ltd. (TLV:BVXV)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 5.27M -43.6% |
| Revenue (ttm) | 4.18M +99.2% |
| Net Income | -26.48M |
| EPS | -11.34 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,358,457 |
| Average Volume | 1,402,253 |
| Open | 50.50 |
| Previous Close | 50.30 |
| Day's Range | 49.20 - 51.30 |
| 52-Week Range | 39.40 - 109.80 |
| Beta | n/a |
| RSI | 53.18 |
| Earnings Date | May 26, 2026 |
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical metho... [Read more]
Full Company ProfileNews
Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility
JERUSALEM, May 20, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company advancing a pipeline of innovative inflammation and immun...
Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe
JERUSALEM, May 15, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company") a biopharmaceutical company focused on inflammation and immunology, today announced t...
Why Is Scinai Immunotherapeutics Stock (SCNI) Up Today?
Scinai Immunotherapeutics stock was on the rise after the company announced a $2.61 million private placement.
Why Scinai Immunotherapeutics Stock Is Skyrocketing 90% Higher Today
Scinai Immunotherapeutics Ltd – ADR (NASDAQ:SCNI) shares are surging Friday morning after the company announced fresh financing tied to a private placement and warrant exercise, helping refocus attent...
Scinai Immunotherapeutics announces $2.61M private placement
Scinai Immunotherapeutics (SCNI) announced that it has entered into a securities purchase agreement with an institutional life sciences investor, as well as with new and existing institutional and acc...
Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing
Financing led by institutional life sciences investor, with participation from new and existing investors Capital expected to support expansion of CDMO platform and advancement of customer programs JE...
Scinai Immunotherapeutics completes strategic reorganization
Scinai Immunotherapeutics (SCNI) announced the completion of a strategic corporate reorganization establishing a dedicated CDMO platform alongside a streamlined R&D organization. Building on its previ...
Scinai Immunotherapeutics targets $5M in CDMO revenue in 2026
Building on the new structure, the company’s 2026 objectives include: CDMO Platform: Scaling operations across both sites and expanding the customer base in the U.S. and Europe; Leveraging the Recipha...
Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities
JERUSALEM, April 6, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI); ("Scinai" or the "Company"), a biopharmaceutical company developing inflammation and immunology therapeutics a...
Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration
JERUSALEM, April 1, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI); ("Scinai" or the "Company"), a biopharmaceutical company operating a dual R&D and CDMO business model designed ...
Scinai Immunotherapeutics highlights expanded CDMO platform
Scinai Immunotherapeutics (SCNI) announced its participation in BIO-Europe Spring 2026, taking place March 23-25 in Lisbon, Portugal. During the conference, the team will meet with pharmaceutical and ...
Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026
JERUSALEM, March 19, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, and th...
Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price
JERUSALEM, March 16, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), today announced that it received a written notification from the Nasdaq Listing Q...
Scinai Immunotherapeutics signs second amendment to PinCell option agreement
Scinai Immunotherapeutics (SCNI) announced the execution of a Second Amendment to its Binding Option Agreement for the acquisition of PinCell S.r.l., and the submission of a revised application under ...
Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept
JERUSALEM, March 2, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI);("Scinai" or the "Company"), today announced the execution of a Second Amendment to its Binding Option Agreemen...
Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform
JERUSALEM, Feb. 25, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI);("Scinai", or the "Company"), today announced that, following an additional review by the Israel Innovation Autho...
Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm
JERUSALEM, Feb. 17, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd . (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company developing inflammation and immunology (I&I) therapeut...
Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL
JERUSALEM, Jan. 7, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI); ("Scinai", or the "Company"), a biopharmaceutical company developing inflammation and immunology (I&I) therapeuti...
Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances
JERUSALEM , Dec. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company developing innovative inflammation and immunology (I&I)...
Scinai Immunotherapeutics awarded grant from Israel Innovation Authority
Scinai Immunotherapeutics (SCNI) announced that it has been awarded a non-dilutive grant of approximately $246,000 from the Israel Innovation Authority. The grant will fund approximately 66% of a $373...
Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities
Grant funds two-thirds of a NIS 1.23 million ($373K) project to strengthen Scinai Bioservices' small-batch fill and finish capabilities, addressing a critical need among early-stage biotech companies ...
Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet
JERUSALEM , Sept. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics’ PC111 featured in peer-reviewed publication
Scinai Immunotherapeutics (SCNI) announced the publication of a new peer-reviewed article in the Journal of Dermatological Treatment validating the disease-modifying potential of PC111, a first-in-cla...
Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN
New data builds on award-winning research and confirms efficacy and safety of PC111 across in-vitro, ex-vivo, and in-vivo humanized models JERUSALEM , July 29, 2025 /PRNewswire/ -- Scinai Immunotherap...
Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025
CEO Amir Reichman to meet investors, pharma partners, and CDMO clients at global biotech conference JERUSALEM , June 12, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharma...